Ligand Pharmaceuticals Inc LGND
We take great care to ensure that the data presented and summarized in this overview for LIGAND PHARMACEUTICALS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding LGND
View all-
Black Rock Inc. New York, NY2.87MShares$314 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.06MShares$225 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.03MShares$112 Million0.06% of portfolio
-
Macquarie Group LTD Australia, C3906KShares$99.2 Million0.12% of portfolio
-
Dimensional Fund Advisors LP Austin, TX745KShares$81.6 Million0.02% of portfolio
-
State Street Corp Boston, MA727KShares$79.6 Million0.0% of portfolio
-
Congress Asset Management CO643KShares$70.4 Million0.54% of portfolio
-
Stephens Investment Management Group LLC607KShares$66.5 Million0.97% of portfolio
-
Chicago Capital, LLC555KShares$60.7 Million1.66% of portfolio
-
Geode Capital Management, LLC Boston, MA464KShares$50.8 Million0.0% of portfolio
Latest Institutional Activity in LGND
Top Purchases
Top Sells
About LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
Insider Transactions at LGND
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Jun 10
2025
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
500
-1.52%
|
$57,000
$114.54 P/Share
|
Jun 06
2025
|
Jason Aryeh Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+1.5%
|
-
|
Jun 06
2025
|
Nancy Ryan Gray Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+13.0%
|
-
|
Jun 06
2025
|
Jason Haas Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+15.47%
|
-
|
Jun 06
2025
|
John W Kozarich Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+2.49%
|
-
|
Jun 06
2025
|
Stephen L Sabba Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+3.45%
|
-
|
Jun 06
2025
|
Martine Zimmermann Director |
SELL
Payment of exercise price or tax liability
|
Direct |
188
-3.96%
|
$19,740
$105.99 P/Share
|
Jun 06
2025
|
Martine Zimmermann Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+20.3%
|
-
|
Jun 06
2025
|
John L Lamattina Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,209
+3.79%
|
-
|
May 15
2025
|
Andrew Reardon CLO & Secretary |
SELL
Open market or private sale
|
Direct |
1,000
-2.95%
|
$104,000
$104.0 P/Share
|
May 09
2025
|
Todd C Davis Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
9,510
+1.95%
|
$989,040
$104.92 P/Share
|
May 09
2025
|
Octavio Espinoza Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
1,500
+2.64%
|
$156,000
$104.15 P/Share
|
Apr 01
2025
|
Stephen L Sabba Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,406
+6.88%
|
$125,112
$52.3 P/Share
|
Mar 04
2025
|
Todd C Davis Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,382
+12.35%
|
-
|
Mar 04
2025
|
Octavio Espinoza Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,484
+22.11%
|
-
|
Mar 04
2025
|
Octavio Espinoza Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-20.94%
|
$575,000
$115.03 P/Share
|
Mar 04
2025
|
Andrew Reardon CLO & Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
6,415
+15.57%
|
-
|
Feb 15
2025
|
Todd C Davis Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,486
-2.4%
|
$778,320
$120.0 P/Share
|
Feb 15
2025
|
Andrew Reardon CLO & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
1,990
-3.33%
|
$238,800
$120.0 P/Share
|
Feb 15
2025
|
Octavio Espinoza Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,027
-3.9%
|
$363,240
$120.0 P/Share
|
Last 12 Months Summary
Other acquisition or disposition | 1.3K shares |
---|---|
Exercise of conversion of derivative security | 33.5K shares |
Grant, award, or other acquisition | 89.7K shares |
Open market or private purchase | 13.5K shares |
Payment of exercise price or tax liability | 35.7K shares |
---|---|
Open market or private sale | 68.9K shares |